Spark Capital
Apollo Hospitals (Buy)
Target: ₹1,870
CMP: ₹1,777.35
In Q1-FY21, Apollo Hospitals’ Healthcare Services (EBITDA loss of ₹100 crore) and AHLL (EBITDA loss of ₹19 crore) were impacted by lockdown. Pharmacy segment (37 per cent y-o-y EBITDA growth) continued its robust performance.
Healthcare Services’ occupancies should improve (guidance of 50-52 per cent in Q2-FY21 vs 38 per cent in Q1-FY21), led by an increase in non-Covid patient volumes and surgical volumes. In addition to volume recovery, ongoing cost rationalisation initiatives should aid margin improvement (guidance to achieve positive EBITDA in Q2-FY21, targeted cost savings of ₹180-200 crore in FY21 vs. ₹100 crore done in Q1-FY21).
Lower capex guidance and proceeds from SAP restructuring (nearly ₹300 crore, transaction completed in September 2020) should ease leverage position (net debt/EBITDA* of 3.5x as of June 2020).
The management expects net debt to remain stable or decline from current levels (₹3,300 crore in June 2020) at FY21-end.
Our SOTP-based target price of ₹1,870 is based on FY22 EV/EBITDA multiple of 16x for APHS’ Hospitals business; FY22 EV/EBITDA multiple of 18x for back-end pharmacy business; equity valuation of AHEL’s stake in associates and joint ventures.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.